Molecular mechanisms of diabetic vasculopathy

Drug Discovery Today: Disease Mechanisms

Volumn 2, Issue 1, 2005, Pages 11-17

  Hamik, Anne ^a   Atkins, G Brandon ^b   Jain, Mukesh K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 4,5 BIS(4 FLUOROANILINO)PHTHALIMIDE; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALAGEBRIUM; ALPHA TOCOPHEROL; AMINOGUANIDINE; BENFOTIAMINE; EPALRESTAT; FIBRIC ACID DERIVATIVE; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; PROTEIN KINASE C BETA; PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN; TOLRESTAT; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

CELL METABOLISM; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; GENETIC MANIPULATION; GENETIC TRANSCRIPTION; HUMAN; HYPERGLYCEMIA; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

EID: 33645089193     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2005.05.030     Document Type: Review

References (44)

1. M.J. Sheetz G.L. King Molecular understanding of hyperglycemia's adverse effects for diabetic complications J. Am. Med. Assoc. 288 2002 2579-2588
2. J.A. Beckman et. al. Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management J. Am. Med. Assoc. 287 2002 2570-2581
3. T. Nishikawa et. al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage Nature 404 2000 787-790
4. A. Ceriello E. Motz Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited Arterioscler. Thromb. Vasc. Biol. 24 2004 816-823
5. J.L. Wautier A.M. Schmidt Protein glycation: A firm link to endothelial cell dysfunction Circ. Res. 95 2004 233-238
6. S.F. Yan et. al. Glycation, inflammation, and RAGE: A scaffold for the macrovascular complications of diabetes and beyond Circ. Res. 93 2003 1159-1169
7. G.L. Bakris et. al. Advanced glycation end-product cross-link breakers: a novel approach to cardiovascular pathologies related to the aging process Am. J. Hypertens. 17 12 Pt 2 2004 23S-30S
8. J.M. Forbes et. al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis Diabetes 53 2004 1813-1823
9. P.J. Thornalley Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts Arch. Biochem. Biophys. 419 2003 31-40
10. H.P. Hammes et. al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy Nat. Med. 9 2003 294-299
11. Y. Naka et. al. RAGE axis: Animal models and novel insights into the vascular complications of diabetes Arterioscler. Thromb. Vasc. Biol. 24 2004 1342-1349
12. C. Falcone et. al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men Arterioscler. Thromb. Vasc. Biol. 25 2005 1032-1037
13. C. Rask-Madsen G.L. King Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance Arterioscler. Thromb. Vasc. Biol. 25 2005 487-496
14. M. Brownlee Biochemistry and molecular cell biology of diabetic complications Nature 414 2001 813-820
15. K.J. Way et. al. Protein kinase C and the development of diabetic vascular complications Diabet. Med. 18 2001 945-959
16. A. Kouroedov et. al. Selective inhibition of protein kinase Cbeta2 prevents acute effects of high glucose on vascular cell adhesion molecule-1 expression in human endothelial cells Circulation 110 2004 91-96
17. O. El-Kabbani et. al. Aldose reductase structures: Implications for mechanism and inhibition Cell. Mol. Life Sci. 61 2004 750-762
18. K.V. Ramana et. al. Activation of nuclear factor-kappaB by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase Diabetes 53 2004 2910-2920
19. J.G. Mabley et. al. NFkappaB1 (p50)-deficient mice are not susceptible to multiple low-dose streptozotocin-induced diabetes J. Endocrinol. 173 2002 457-464
20. M. Yuan et. al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta Science 293 2001 1673-1677
21. M.A. Hofmann et. al. Insufficient glycemic control increases nuclear factor-kappa B binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes Diabetes Care 21 1998 1310-1316
22. A.M. Schmidt et. al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes J. Clin. Invest. 96 1995 1395-1403
23. M. Morigi et. al. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion J. Clin. Invest. 101 1998 1905-1915
24. N. Tanaka et. al. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17 beta-estradiol through Sp-1 in human vascular endothelial cells J. Biol. Chem. 275 2000 25781-25790
25. K.K. Yerneni et. al. Hyperglycemia-induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells Diabetes 48 1999 855-864
26. C. Peiro et. al. Glycosylated human oxyhaemoglobin activates nuclear factor-kappaB and activator protein-1 in cultured human aortic smooth muscle Br. J. Pharmacol. 140 2003 681-690
27. M. Guha et. al. Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways J. Biol. Chem. 275 2000 17728-17739
28. F. Miao et. al. In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions J. Biol. Chem. 279 2004 18091-18097
29. N. Nakamura et. al. Induction of aldose reductase in cultured human microvascular endothelial cells by advanced glycation end products Free Radic. Biol. Med. 29 2000 17-25
30. S. Srinivasan et. al. Hyperglycaemia-induced superoxide production decreases eNOS expression via AP-1 activation in aortic endothelial cells Diabetologia 47 2004 1727-1734
31. Y.Q. Chen et. al. Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells J. Biol. Chem. 273 1998 8225-8231
32. X.L. Du et. al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation Proc. Natl. Acad. Sci. USA 97 2000 12222-12226
33. R.N. Hasan et. al. Differential regulation of early growth response gene-1 expression by insulin and glucose in vascular endothelial cells Arterioscler. Thromb. Vasc. Biol. 23 2003 988-993
34. P.O. Hassa M.O. Hottiger The functional role of poly(ADP-ribose)polymerase 1 as novel coactivator of NF-kappaB in inflammatory disorders Cell. Mol. Life Sci. 59 2002 1534-1553
35. F.G. Soriano et. al. Diabetic endothelial dysfunction: Role of reactive oxygen and nitrogen species production and poly(ADP-ribose) polymerase activation J. Mol. Med. 79 2001 437-448
36. C. Szabo et. al. Poly(ADP-ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity Circulation 106 2002 2680-2686
37. J.H. Li et. al. Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: Implications for diabetic renal and vascular disease FASEB J. 18 2004 176-178
38. N. Kanie et. al. Relationship between peroxisome proliferator-activated receptors (PPAR alpha and PPAR gamma) and endothelium-dependent relaxation in streptozotocin-induced diabetic rats Br. J. Pharmacol. 140 2003 23-32
39. T. Takagi et. al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: An intravascular ultrasound scanning study Am. Heart J. 146 2003 E5
40. H. Koshiyama et. al. Rapid communication: Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes J. Clin. Endocrinol. Metab. 86 2001 3452-3456
41. M. Tonelli et. al. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency Kidney Int. 66 2004 1123-1130
42. Z. Lin et. al. Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function Circ. Res. 96 2005 e48-e57
43. Sen-Banerjee, S. et al. KLF2 as a novel mediator of statin effects in endothelial cells. Circulation (in press)
44. P.A. Watson et. al. Diabetes-related changes in cAMP response element-binding protein content enhance smooth muscle cell proliferation and migration J. Biol. Chem. 276 2001 46142-46150